Overview
Plain-language guide
Designed for research into Cachexia research, Appetite-loss research, Catabolic-disease research. It remains investigational for these uses.
It switches on a receptor involved in appetite and growth-hormone release. Short-term hormone release does not by itself prove lasting muscle gain.
Clinical mechanism
Groups investigational assets designed to activate ghrelin receptors and influence appetite or endocrine signaling.
Applications
Human evidence
Early or mid-stage human data exist, but confirmation, replication or long-term follow-up remains incomplete.
Tier 2Preclinical evidence
Mechanistic and preclinical findings are tracked separately and are not treated as proof of human clinical benefit.
Muscle & recovery profile
Each signal is scored independently from 0–5. There is no composite “best” score.
Evidence classes
What has been studied
- Programs have examined appetite, body weight, lean mass and function in catabolic conditions.
What is not established
- Changes in appetite or lean mass do not automatically establish strength or recovery benefit.
Studied populations
- People with cachexia, appetite loss or catabolic illness in clinical research
Major limitations
- Muscle-specific outcomes may be secondary, exploratory or absent from available studies.
- Findings from one population, formulation or indication should not be generalized to another.
Evidence-source categories: primary regulatory record, clinical trial registry, peer reviewed literature. These editorial source categories require record-level primary links before publication-grade citation export.
Regulatory status
Investigational. Regulatory status is product- and jurisdiction-specific and does not automatically follow from an evidence score.
Safety
Uncertain or Concerning
- Adverse effects vary by product and indication
- Contraindications and interactions require label review
Interactions
Review the current product label and indication-specific literature for pharmacologic and absorption interactions.
Treatment pattern
Treatment patterns are product-, indication- and clinician-specific; this educational profile does not provide dosing guidance.
Manufacturing and quality
Approved-product identity, formulation and quality controls must not be extrapolated to compounded or RUO copies.
Sponsor and development history
Multiple developers · Class watchlist. Development programs and ownership can change; confirm current sponsor disclosures.
Sources
- 01Primary regulatory record
Source record prepared for primary-reference linking in the Supabase-backed editorial workflow.
- 02Clinical trial registry
Source record prepared for primary-reference linking in the Supabase-backed editorial workflow.
- 03Peer-reviewed literature
Source record prepared for primary-reference linking in the Supabase-backed editorial workflow.
Gaps and unverified claims
- Long-term outcomes and real-world safety are not yet established.
- Current phase and catalysts require primary-source confirmation.
Last reviewed
August 5, 2026 · Reviewed